This could be due to the lower expression of ALDH3B1 that causes an inadequate response to platinum-based chemotherapy leading to higher systemic toxicity and increased mortality among the advanced-stage (IIIB and IV) NSCLC patients in our sample population. Here, ALDH3B1 is linked to non-small cell lung carcinoma.